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The therapeutic potential of Fecal Microbiota Transplantation (FMT) is greatly 
proved worldwide in the recent years. The use of FMT is now an accepted treat-
ment modality and effective standard of care for some patients owing to its success 
in treating recurrent Clostridium Difficile Infection (rCDI). However, it is still 
evolving and longer term follow-up data regarding safety are required. Post-FMT 
serious adverse events (SAEs) have been varied between studies, however have 
included significant morbidity necessitating hospital admission and mortality in 
the follow-up period. The follow-up of FMT recipients should be long enough to 
completely establish efficacy/adverse events. Furthermore, it is recommended 
that FMT should be offered with caution to immunosuppressed patients, in whom 
FMT appears efficacious without significant additional adverse effects. In the wake 
of COVID-19 situation, stringent policies in screening the FMT donors have to be 
put forth to ensure patient safety. There is a need for high-quality, large, prospec-
tive, randomized controlled trials and long-term follow-up investigating screened 
donors and recipients to evaluate the long term safety and the risk–benefit profile of 
this promising therapy.
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1. Introduction
Owing to the success of Fecal Microbiota Transplantation (FMT) in treating 
various diseases, there’s a growing demand for standardizing the preparation 
of fecal material, using accepted standards for the delivery, ensuring safety for 
the recipient, and monitoring long-term outcomes. [1] The most robust clinical 
evidence is driven by studies of FMT as a treatment for refractory or recurrent 
Clostridium difficile infection (CDI). Despite the progress in studying the FMT 
therapy in CDI, there are no prospective studies assessing the safety or efficacy 
of FMT in IBD. However, critics still have significant concerns regarding the 
acceptability of FMT, the ethical issues associated with risk and studying FMT in 
patients with severe disease. [2] Despite the enthusiasm regarding FMT research, 
the pertinent questions remain, apart from those addressing potential therapeu-
tic indications. These comprise whether the TM could be whole flora extract or 
cultured TM, methods of administration, implantation success, and immunologic 
responses, as well as the long-term safety implications of altering the microbiota 
composition. [3] In the first clinical trial that assessed this treatment modality, FMT 
proved so superior to standard antibiotics that the study’s data and safety monitor-
ing board stopped enrollment early, concluding that it was unethical to hold back 
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the treatment from the members of the control group. However, it is crucial to 
understand that diseases that have been linked to the microbiome may surface years 
post the procedure. As such, there remains a requirement for more investigation of 
the safety profile of FMT in the extreme long term. [4]
2. Safety concerns & the significance of donor screening protocol
FMT as a treatment modality is considered unique owing to the difficulty of 
its characterization and the simplicity of its production, and each of these charac-
teristics raises special safety concerns. First, the complexity of the communities 
of microbes in stool and the variability across samples makes it challenging to 
guarantee the contents from one batch to another. Per se, ongoing monitoring 
with regards to the presence of possible pathogens is vital for maintaining a safe 
product and should either be considered part of the approved manufacturing 
process or a condition imposed on manufacturers. Second, even though there is 
little scope that patients will manufacture traditional small molecule therapies 
in their lavatories, processing stool for transplantation at a basic level needs very 
little training or equipment. Patient online forums comprise lengthy thorough 
instructions coupled with discussions regarding best practices for mixing stool in 
a low-cost blender and administering it through enema. There is a considerable 
risk of pathogen transmission from improperly screened and handled tool due to 
unsupervised, do-it-yourself procedures. Few healthy subjects would be considered 
eligible for stool donation for fecal transplantation. Only six per cent of prospective 
donors to OpenBiome clear the full screening process. This includes a thorough 
109-item clinical evaluation administered by a nurse or physician, and 30 stool and 
blood screens. It is wise to be very cautious about screening for diseases that are 
potentially transmitted by the microbiome. For instance, investigators have notably 
linked the microbiome to diverse parameters such as obesity, metabolic syndrome, 
and behavior. Likewise, it is just as crucial to accumulate longitudinal safety data to 
identify any conditions that may be transmitted via stool of which we are unaware. 
Thus, taking into account the known and unknown risks that come with improper 
donor screening and inadequate patient follow-up, the ease with which patients may 
prepare and administer fecal transplants themselves without medical supervision, 
any regulatory outcome that results in restricted access by either limiting supply or 
significantly increasing the cost of therapy should be adopted very cautiously. [4] 
Hence, donor screening protocol is a crucial step. Preferred stool donors are healthy 
individuals without pre-existing disease or risk factors for disease. These individu-
als are recruited by stool banks and undergo a detailed screening process that 
includes a questionnaire to exclude those with disease, exposure to transmissible 
diseases, or behavioral risk factors for transmissible diseases. Disease exclusions 
comprise, but are not limited to, blood- or stool-borne infections, gastrointestinal 
disorders, malignancy, atopy, metabolic syndrome and autoimmune diseases. 
Individuals who have recently taken antibiotics or have traveled to areas with a high 
risk of traveler’s diarrhea are excluded. [5]
3. The gaps in understanding FMT safety risk
Many researchers state that FMT is “safe” based on a multitude of uncontrolled 
trials without a placebo control. Closer examination of adverse event (AE) report-
ing, however, recommends a need for caution on several grounds. Some of the 
factors that could be responsible for these gaps are potential under-reporting of 
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adverse events and the uncontrolled design of FMT trials. [6] In the largest FMT 
trial so far, 219 subjects (mean age, 73 years) were randomized to fresh or frozen 
FMT via enema. Six deaths (5.6%) occurred in the frozen FMT arm, and 11 deaths 
(11.7%) occurred in the fresh FMT arm; none were attributed by the investigators 
to FMT. [7] Although the CDI morbidity and mortality rates have been reported to 
be as high as 15%, it is difficult to understand which AEs may be treatment-related 
without the benefit of a placebo-controlled arm. [6] A few FMT proponents have 
debated that some patient subgroups, such as immunocompromised hosts, often 
do not qualify for placebo-controlled trials and need open access to FMT. [8] Still, 
implicit in this statement is the implication that FMT has been demonstrated to be 
efficacious and safe in this patient population when there are no controlled trials to 
support such assumptions. Furthermore, comparison of AE rates between 2 FMT 
products is useful. [6] In a randomized, double-blind, placebo-controlled phase 2B 
trial of a stool-derived microbiome drug product, RBX2660, 64% of recurrent CDI 
patients reported an AE; the distribution of these AEs was comparable by treatment 
arm (2 doses of placebo vs. 2 doses RBX2660 vs. 1 dose RBX2660/placebo). [9] On 
the other hand, a stool bank (OpenBiome, Cambridge, MA, USA) reported 42 AEs 
in 2050 subjects who underwent FMT, for an event rate of 2%. Besides, none of the 
AEs was judged to be “definitely related to FMT”. Attributing the dramatic differ-
ences in event rates to major differences in the products themselves is challenging, 
as both are stool-derived. The main differences seem to be the methodologies used 
in collection of AEs and reporting. In the randomized placebo-controlled phase 
2b trial of RBX2660, AEs were systematically collected on a prospective basis and 
investigators were mandated to allocate causality. [6] On the contrary, OpenBiome 
asks clinicians to retrospectively report, and the stool bank portrays the association 
of the product to AEs rather than the clinicians. [6, 10] This kind of methodol-
ogy is disposed to bias. There is a chance of retrospective reporting missing the 
links between infections and FMT if the patient is assessed by a different health 
care provider who does not recognize the temporal relationship. [6] Serial FMT 
Interventions with invasive procedures is another matter to worry about. A trial 
reported 90% efficacy in 20 subjects managed with FMT, although on delving into 
the article, it was found that the first-dose efficacy was only 65%. [11] In order to 
reach 90% efficacy, multiple infusions (2–4 per patient) were given. Repeat infu-
sions through invasive techniques such as colonoscopy, should also be weighed in 
the risk/benefit analysis of any procedure, and first dose efficacy rates need to be 
reported with clarity. [6]
4. Safety of FMT in C. difficile infections
Arguably the best example of harnessing the gut microbiota to manage a disease 
is the use of F) for the treatment of CDI, where the most convincing safety and 
efficacy data for use of FMT has shifted the treatment paradigm and revolutionized 
its management. [12] Most patients with CDI are aged and often with present with 
co-morbidities, but many other recipients of FMT are likely to be much younger. 
For such patients, the long-term consequences of gut microbiome manipulation 
have yet to be understood. There are, for instance, anecdotal reports of numer-
ous changes that have occurred post FMT. [13] These include reversal of immune 
thrombocytopenic purpura and neurological symptom reversal in three patients 
with multiple sclerosis. [14, 15] In two patients, the resistant coliforms present 
before FMT were supplanted by ciprofloxacin-sensitive coliforms after FMT. FMT 
for refractory CDI lead to an apparent improvement in the related urinary organ-
isms exhibiting ‘significantly decreased drug resistance.’ This was further supported 
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by two case reports using FMT to decolonize patients with multi-drug-resistant 
carbapenemase-producing strains of Klebsiella pneumoniae. Other researchers have 
observed improvement in pre-existing allergic sinusitis and arthritis. In a case series 
of patients with Crohn’s disease treated with FMT, eight out of 11 patients noted 
relief of concomitant ‘skin lesions’, a phenomenon also observed in another group 
using FMT to treat ulcerative colitis where three cases demonstrated improvement 
in ‘skin problems’ as well as decreased insulin requirements in a diabetic patient. 
Furthermore, a case report has been published linking FMT to the development 
of obesity. [13] FMT for recurrent C. difficile possesses a good short-term safety 
record. Very few adverse effects are directly attributed to the procedure. Most 
reported adverse events have been self-limiting gastrointestinal symptoms compris-
ing abdominal cramps, diarrhea and constipation, which resolved within one week. 
At least two deaths from aspiration pneumonia related to sedation administered at 
the time of FMT have been reported. At least one death from transmission of a mul-
tidrug resistant Escherichia coli organism has been reported, however the donor in 
this case had not been tested for this organism. However, these deaths are relatively 
less compared to the large number of FMTs performed. [5] A long-term follow-up 
study by Brandt et al., patients who had colonoscopic FMT for RCDI≥3 months 
before the study were asked to completed a 36-item questionnaire that solicited 
pre-FMT, post-FMT and donor data. Out of 77, 4 patients reported a new medical 
condition after FMT including peripheral neuropathy, Sjogren’s disease, idiopathic 
thrombocytopenic purpura and rheumatoid arthritis. A total of 7 of the 77 patients 
died at the time of the study. The causes of death were metastatic colon cancer 
(present before FMT), metastatic ovarian cancer, pneumonia (secondary to non-
enteric organism), myocardial infarction, stroke, sepsis in a patient with longstand-
ing CD 5 months after FMT, and one patient deceased while on hospice care from 
unknown cause. None of these causes seemed to be attributable to FMT. [16, 17]
5. Safety of FMT in ulcerative colitis (UC)
UC, a major subtype of IBD, perhaps denotes one of the most robust potential 
indications for FMT after RCDI. [18] Rossen et al. evaluated the efficacy and safety 
of FMT in 37 patients with UC in a double-blind randomized trial, and noted mild 
adverse events in the majority of patients (64%), including transient borborygmus 
(49%), increased stool frequency (34%), vomiting in 2 patients and transient fever 
in 2 patients. Most adverse events resolved spontaneously within 2 days. There were 
no infectious complications observed. Four SAEs happened, but were not related 
to FMT itself. It has been noted that some patients develop self-limited fever and 
temporary elevation of CRP and IL-6 following FMT, but were considered non-
significant, as patients did not show deterioration. [16] Fang et al. concluded that 
single fresh FMT is an effective and safe strategy to induce long-term remission 
in patients with active UC and could be expected to be an alternative induction 
therapy for recurrent UC, even primary UC. None of the patients suffered from 
other chronic diseases such as immune system diseases, non-alcoholic fatty liver 
disease and all patients demonstrated good tolerance to FMT treatment. [18]
6. Safety of FMT in inflammatory bowel disease (IBD)
Owing to its success in treating rCDI, the use of FMT became rapidly accepted. 
[1] It appears that most patients with IBD managed with FMT for RCDI tolerate the 
procedure well; nevertheless, there appears to be a potential risk of precipitating a 
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flare. Whether this flare is related to FMT or as part of the natural course of IBD is 
ambiguous. [16] In a retrospective case series by Kelly et al., a few patients with IBD 
were reported to present with ‘IBD flare’ post FMT (14%). It is worth nothing that 
patients with IBD did not experience a higher incidence of SAEs (11%) or adverse 
events (14%) compared with patient immunocompromised due to other conditions 
(18% SAEs, 16% AEs, p ≤ 0.3224). [19] The definite mechanism of IBD flare post 
FMT is still ambiguous, although Quera et al. suggested that transient bacteremia 
may lead to an altered intestinal permeability, resulting in a flare. [20] In their 
open-label, single-center prospective trial, Goyal et al., concluded that a single 
FMT is relatively safe and can result in a short-term response in young patients with 
active IBD. Samples from responders had significantly increased Fusobacterium 
prior to FMT and showed more significant microbiome changes compared with 
non-responders after FMT. [21] Further research is needed to discern whether 
the abundance of Fusobacterium, an organism associated with numerous adverse 
health outcomes, has prognostic value in the setting of FMT for IBD. [22]
7. Safety of FMT in immunocompromised patients
The safety of using live microorganisms in a treatment modality such as FMT 
remains unclear in certain patient groups—particularly, in severely immunosup-
pressed patients. [23] Few experts are concerned that there may be a greater risk 
for infection post FMT in patients with immunocompromised status. Kelly et al. 
examined FMT in 80 immunocompromised patients of CDI and observed that 
there were no infection events related to FMT while high cure rates of 78% follow-
ing a single FMT were noted. [20] Among the different FMT delivery methods used, 
there were no observed differences in the proportion of adverse events. [7, 24, 25] 
Nevertheless, long-term immunologic effects of FMT is another matter of concern, 
but very little relevant data is available. [20] Numerous case reports have indicated 
that there might be some undetermined association between FMT and certain con-
ditions, including peripheral neuropathy, idiopathic thrombocytopenic purpura, 
Sjogren’s syndrome, and rheumatoid arthritis. [17] Presently, the definite periodic-
ity and duration of follow-up post FMT for monitoring of long-term adverse events 
are not established. The European consensus proposed that the follow-up period 
post FMT in CDI patients should be minimum 8 weeks, and the contents of follow-
up must comprise clinical and analytical information. [26]
8. Adverse events reported in past clinical literature
Most clinical trials and systematic reviews demonstrated that some minor adverse 
events, like abdominal discomfort, diarrhea, constipation, and low-grade fever, 
were transiently observed post FMT, whereas uncommon severe side effects were 
often related to the possible complications of endoscopy and sedation. [20, 27–29] 
According to the past clinical literature, the two most common side effects of FMT 
observed are bloating and loose stools for the first 24 hours. These usually resolve 
soon thereafter and most patients usually have formed stool by 1–2 weeks. The clini-
cians do not recommend stool testing for resolution in those with formed stool, but 
is considered if 3 or more diarrhea stools per day occur post few weeks. It is crucial 
to note that the polymerase chain reaction test for C. difficile toxin may remain 
positive for 30 days after a successful treatment, which is another reason not to test 
asymptomatic patients who underwent FMT. An unclear presentation is abdominal 
cramping and intermittent frequent bowel movements occurring in a patient who 
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might be a carrier of C. difficile and who is a FMT recipient. These patients are most 
likely to have post-infectious IBS. Hence, the clinician should ideally be able to 
differentiate between post-infectious IBS and rCDI in order to avoid unnecessarily 
repetition of FMT. [1] In a systematic review by Marcella et al., FMT-related adverse 
events were summarized. (Table 1) Largely, 85 unique types of AEs were reported in 
24% of FMT procedures (1347/5688) during or after FMT, including 6% (246/4241) 
of patients with SAEs. [30]
Although FMT may seem “natural” and safe, possibly even “frugal,” clinicians 
are concerned about the long-term effects that donors’ intestinal microbes may have 
on patients receiving FMT. [31] For instance, the gut microbiota has been shown 
to be a possible transferrable agent of risk or phenotype in multiple disorders, 
including obesity, cardiovascular disease, and autoimmune disorders, such as type 
1 diabetes. [32, 33] Furthermore, the gut microbiota has been found to interact 
with the central nervous system and to affect brain chemistry and behaviors. [34] 
Theoretically, FMT could bring about the transmission of anxiety and depression, 
Adverse Events % of Patients Affected
Diarrhea 10.00%













Sore throat, Rash, Skin erythema, Pruritus 0.14%
Anorectal discomfort, Headache 0.12%
Aspiration pneumonia, CMV infection, Rectal bleeding, Chills 0.11%
Bacteremia, Death 0.09%
Mucoid stool, Transient borborygmus 0.07%
Diverticulitis 0.05%
Peripheral Neuropathy, Norovirus gastroenteritis, Rhinorrhea, 
Herpes zoster, Decreased appetite, Dizziness, C. perfringens 
Infection
0.03%
Sjogren’s disease, ITP, Rheumatoid arthritis, Minor mucosal tear 
during colonoscopy, Hematemesis, Chest distress, Testicular 
pain, Myasthenia gravis, Hot flashes, Allergic bronchitis, 
Dehydration, Rectal prolapse, Appendicitis, URTI, Pancreatitis, 
Stuffy nose, Depression, Anorexia, Soling of transplant, Vertigo
0.02%
Table 1. 
FMT related adverse events [30].
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autism, or neurological conditions, such as Parkinson’s disease. However, most of 
these effects have only been observed in preclinical studies. [32]
9.  The different AEs report in randomized controlled trials (RCTs) and 
non-controlled studies
In a systematic review by Marcella et al., twenty studies of RCTs included 558 
patients: 222 with IBS, 138 with UC, 70 with CDI and few patients with cirrhosis, 
constipation, obesity, autism spectrum disorder and hepatic encephalopathy. While 
in non-controlled studies, the most common indication was CDI followed by IBD. 
When compared to RCTs, non-controlled studies demonstrated a lower trend of 
FMT-related AEs rate. Nevertheless, all FMT-related SAEs were reported in non-
controlled studies. This result should not be considered as a premise as patients 
with severe cases or immunocompromised were essentially excluded from RCT. 
Therefore, RCT results should not be referred to as the representative as a whole.
10. AEs in populations with different delivery route
The incidence of FMT-related AEs by route of delivery comprised colonic 
transendoscopic enteral tubing (TET) (6%), colonoscopy (15%), enema (26%), 
capsule (29%), midgut tube (29%) and gastroscopy (32%). Upon analysis, the 
incidence of FMT-related AEs was more common in patients who had FMT via the 
upper GI routes than lower GI routes (28.8% vs. 17.5%). This result is in conjunc-
tion with the incidence of FMT-related SAEs in upper and lower GI route (1.4% vs. 
0.9%). Additionally, the SAEs that occurred in FMT recipients via gastroscopy and 
mid-gut tube were all delivery-related SAEs. This confers to a belief that patients 
likely experienced SAEs caused by invasive endoscope procedures rather than the 
microbiota-related SAEs for upper GI routes (except for capsule). On the contrary, 
for lower GI routes and capsule, a plethora of SAEs were microbiota-related. Kunde 
et al. outlined the tolerability of FMT in children with UC and intolerance with 
immediate leaking of enemas happened in one patient. Colonic TET was in recent 
times used as the delivery of washed microbiota for the elderly, adults and children 
to ensure the whole-colon administration of microbiota and to meet the patient’s 
needs that required multiple FMTs. [30] AEs such as nausea (1%), pharynx discom-
fort (5%) and rhinorrhea (1%); and procedure-related: mild pharynx bleeding (1%), 
epistaxis (5%) and unplanned extubation (2%) were reported in a study compris-
ing patients who underwent mid-gut TET. [35] Ekekezie et al. published a survey 
regarding do-it-yourself (DIY) FMT that consisted of 84 respondents. [36] The 
survey demonstrated that DIY FMT was most commonly used in IBD (35%) and IBS 
(29%) patients. AEs, such as abdominal pain, flatulence and bloating, changes in 
mood, fever, infection and hospitalization were reported in 12% of the participants. 
Self-administration of home FMT via enema was observed in two articles, which 
allowed eight patients to complete 11 courses of FMT in total. About 87.5% (7/8) of 
patients benefited from this. Three patients developed AEs, two patients had urinary 
tract infection post-FMT deemed to be not related to the FMT and one patient expe-
rienced severe bloody diarrhea, weakness, abdominal pain and weight loss several 
weeks post-FMT, which was due to CMV infection. [30] CMV is observed in up to 
one-third of IBD patients with the glucocorticoid-refractory disease. [37] Moreover, 
CMV may arise inadvertently from an unconventional method of home or self FMT 
preparation. Hence, there is a need for increased awareness around DIY-FMT and 
research around this phenomenon, which may leverage public health. [30]
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11. Informed consent
Informed consent usually presupposes three elements such as capacity to 
consent, voluntariness, and information. [38] It is not capacity to consent but 
inadequate information that may pose problems with regards to FMT. [32] In 
recurrent and refractory CDI cases, FMT could be considered in the “transition 
zone” between experimental research and standard of care. [32, 39] Even though 
innovative interventions are generally regulated less strictly than new drugs or 
biological products, their “experimental” nature does imply special ethical require-
ments for informed consent. [32] Despite the fact that there are no formal standards 
for the content of informed consent for “transition zone” interventions, it is usually 
accepted that such discussions should include the following components: the inno-
vative nature of the procedure, the provider’s experience with the procedure, the 
risk–benefit profile including unknown risks, the (lack of) evidence, and alterna-
tives to the innovative intervention. [32, 40]
12. Washed microbiota transplantation
The FMT procedure using washing process was coined as washed microbiota 
transplantation (WMT). FMT on the basis of washed microbiota preparation 
has been shown to reduce adverse events caused by traditional fecal suspension 
preparation and significantly improve the efficacy. [41] Population evidence 
demonstrated the washed microbiota preparation with microfiltration based on an 
automatic purification system followed by repeated centrifugation plus suspension 
for three times significantly decreased the adverse events related to FMT. [42] With 
the goal to improve the safety of FMT, studies regarding improved methodology 
of fecal microbiota preparation known as WMT continue to accrue in China since 
2014. WMT is based on the principle of automatic filtration and washing process 
and the related delivery. [30, 42, 43] The improved safety of WMT was reinforced 
by the metagenomics next-generation sequencing and metabolomics analysis that 
demonstrated more types, amount of viruses, and pro-inflammatory mediators 
were washed out during the washing process. [30]
13. FMT in the COVID-19 pandemic
Owing to the outbreak of COVID19, healthcare facilities have intensively 
decreased elective activities both to avoid potential transmission of the virus and to 
shift human and structural resources to the management of COVID-19. [44] In the 
wake of COVID-19 situation, stringent policies in screening the FMT donors have to 
be put to ensure the patient safety. [30] Due to the potential risk of transmission of 
SARS-CoV-2 via Fecal Microbiota for Transplantation (FMT), FDA has determined 
that additional precautions are needed for any investigational use of FMT, whether 
under an Investigational New Drug Application (IND) on file with the FDA or 
under FDA’s enforcement discretion policy. The following recommendation has 
been made by FDA. It has already notified all IND holders of the need for additional 
precautions namely:
No clinical use of FMT product manufactured from stool donated on or post 
December 1, 2019, until further screening and testing procedures and changes 
to the informed consent process are implemented for such stool donations as 
defined below:
9
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1. Screening of stool donor, including an evaluation of whether, since December 
1, 2019, the donor was diagnosed with laboratory-confirmed SARS-CoV-2 
infection, experienced symptoms of COVID-19 not explained by another 
diagnosis, or was exposed to a suspected or confirmed case of COVID-19.
 ○ In any occurrences of suspected or confirmed SARS-CoV-2 infection or 
exposure as described above, exclusion of the donor from further dona-
tions is recommended. Also, it is recommended that there should not be 
any clinical use of any FMT product manufactured from stool donated by 
the affected donor beginning 4 weeks prior to the suspected or confirmed 
SARS-CoV-2 infection or exposure should be avoided.
2. Performing test of the stool donation or stool donor for SARS-CoV-2 virus  
or RNA.
 ○ Tests may include testing upper respiratory clinical specimens (e.g., nasal 
swabs) or other clinical specimens (e.g., rectal swabs or stool donations).
 ○ If SARS-CoV-2 is identified, exclusion of the donor from further donations is 
recommended. Also, it is recommended that there should not be any clinical 
use of any FMT product manufactured from stool donated by the affected 
donor beginning 4 weeks prior to the first positive test.
3. In the context of informed consent process, it is crucial to convey to the FMT 
recipient that healthy, asymptomatic stool donors may potentially be infected 
with SARS-CoV-2, explain the testing approach and other strategies used to 
alleviate the risk of SARS-CoV-2 transmission, and advise the FMT recipient of 
the limitations of testing and risk mitigation strategies. [45]
In their position paper, Ianiro et al., depending on the available clinical evi-
dence, the panel provided guidance on issues relating to the impact of COVID-19 
on FMT, including selection of patient, selection and recruitment of donor, FMT 
procedures, patient follow-up and further research activities. Few feasible security 
measures have been proposed in this article so as to assure a safe cohabitation with 
COVID-19 in the near future. Following are the recommendations for every step of 
the FMT procedure to mitigate the potential risk of SARS-CoV-2 transmission:
Outpatient assessment:
Remote assessment (teleconsultation) is recommended.
If remote assessment not possible: Checkpoint at entrance (body tempera-
ture; patients must wear surgical mask; hand wash; no company admitted) is 
recommended.
COVID-19 screening (exposure and medical history, symptoms, laboratory 
analyses) is recommended.
If clinical suspect of COVID-19, nasopharyngeal swab must be carried out.
Inpatient assessment:
Exclusion of COVID-19 via tests. (nasopharyngeal swab, laboratory exams, if 
fever or respiratory distress conduct chest CT scan).
Isolation is recommended. (contact precautions and droplets in air).
If patient is COVID-19 positive:
• Dedicated COVID-19 wards and dedicated healthcare professionals 
recommended.
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• Dedicated radiology and invasive procedures recommended.
• Assess the risk/benefit profile of FMT procedure.
Donor screening:
Remote evaluation (The screening could be done through teleconsultation).
Screening for COVID-19 (Details about exposure to confirmed cases, medical 
history, symptoms, if any).
Laboratory examinations are recommended (standard blood and stool tests plus 
nasopharyngeal swab and serology for SARS-CoV-2).
Donors who test positive must be excluded from donation and previously 
donated stool, up to 4 weeks before the occurrence of symptoms/COVID-19 diag-
nosis, should be discarded as initial clinical evidence proposes that SARS-CoV-2 is 
detected in stools up to 4 weeks post infection.
Sample donation:
A dedicated toilet at the stool bank should be reserved for collection of stool, 
and high-touch surface areas should be cleaned post each donation.
Repeat standard and COVID-19 screening interview is recommended 
for donors.
Checkpoint at the entrance (body temperature, subjects must wear surgical 
mask, hand wash, company forbidden) is recommended.
Direct stool testing for SARS-CoV-2 and/or common pathogens and quarantine 
approach as potential alternative is recommended.
Sample handling:
Stool sample transferred to laboratory by dedicated healthcare workers is 
recommended.
Retention of stool samples for ‘look-back’ testing is suggested.
Stool processing that conforms to local standard operating procedures and 
biosafety protocols; at minimum, biosafety level 2 is recommended.
FMT using endoscopic procedure:
• Patients undergoing outpatient elective endoscopic FMT should have tempera-
ture checked and be questioned about possible symptoms.
• Dedicated healthcare professionals for COVID-19 is recommended.
• Staff present in the endoscopic room must be protected for aerosol generating 
procedures.
• Patients need to wear surgical mask.
• Outpatient discharged post brief observation, medical and nurse staff report 
follow-up instructions to caregivers via teleconsultation.
Follow-up:
Follow-up visits should preferably take place via teleconsultation, outpatient 
visits should be limited to cases where in-presence assessment is mandatory. [44]
14. Recommendations for future clinical trials
The safety of any investigational product is best understood with respect 
to a placebo-controlled trial with appropriate sample size with an adequate 
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follow-up period. A national FMT registry, supported by a grant to the American 
Gastroenterology Association from the National Institutes of Health, has been 
initiated to address the limited knowledge of the long-term risks of FMT. [6] This 
registry aims to collect the efficacy and safety data on 4000 patients who undergo 
FMT for up to 10 years to understand the long-term risks and benefits of FMT. [30] 
However, the study results will not be available for many years to come. The impor-
tant reason for caution regarding potential long-term consequences of FMT is the 
ever-increasing list of diseases related to the microbiome. [6, 46] Clinicians should 
be aware of data limitations when counseling patients concerning any investiga-
tional therapy. The following recommendations could be made for future FMT 
based trials and for reporting of data to improve the fundamental understanding of 
FMT safety and efficacy:
Exclusive employment of toxin testing to ensure selection of patients with true 
recurrent CDI.
• Enrolment of subjects with acute-onset CDI.
• Consideration of key exclusion criteria such as long-term suppressive  
antibiotics for CDI.
• Reporting of the number of treatments required to achieve clinical resolution, 
as repeated FMT treatments carry procedural risks, depending on route of 
administration.
• Statistical interpretation should take into account loss to follow-up and other 
AEs that lead to treatment discontinuation, which are considered treatment 
failures in most clinical trials.
• Large double-blind, placebo-controlled trials are important for adequate evalu-
ation of the efficacy and safety of any investigational intervention, including 
FMT. On the other hand, future comparator trials with vancomycin pulse-
taper regimens should be considered to fully evaluate if FMT offers additional 
advantages over other recommended therapeutic approaches. [6]
15. Concluding remarks
Over the last decade, much progress has been made studying FMT for the 
management of CDI, and there are multiple ongoing studies also assessing it as a 
therapy for other conditions. Nonetheless, there is still much to learn regarding 
the gut microbiome and its role in disease physiology and treatment. Both physi-
cians and patients will benefit from a better understanding of the risks of FMT 
and delineated protocols to assess adverse events, complications, and follow-up. 
There is a need for high-quality, large, prospective, randomized controlled trials 
and long-term follow-up investigating screened donors and recipients to evaluate 
the long term safety and the risk–benefit profile of this promising therapy. [47] 
Furthermore, immunocompromised patients represent a special patient population, 
and designing a randomized controlled trial that addresses the safety and efficacy 
of FMT among these individuals will definitely be a welcoming step forward. [48] 
Mandatory stringent screening guidelines for stool donors are the need of the hour, 
even though screening cannot prevent unanticipated emerging infections. [6] The 
COVID-19 pandemic is challenging the healthcare systems globally, and it is reason-
able to assume that it will be present also in the near future, compelling us to adjust 
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the overall clinical-procedural standards. Lastly, the development of investigational 
microbiome therapeutics with defined microbial consortia will provide greater 
confidence in drug purity, identity, and potency, in addition to risk mitigation for 
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Acronyms and abbreviations
FMT fecal microbiota transplantation
rCDI clostridium difficile infection
UC ulcerative colitis
IBD inflammatory bowel disease
WMT washed microbiota transplantation
SAEs serious adverse events
RCTs randomized controlled trials
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
TET transendoscopic enteral tubing
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
13
Safety & Potential Risks with Fecal Microbiota Transplantation
DOI: http://dx.doi.org/10.5772/intechopen.95907
References
[1] Kim KO, Gluck M. Fecal microbiota 
transplantation: an update on clinical 
practice. Clinical Endoscopy. 2019 
Mar;52(2):137.
[2] Kahn SA, Vachon A, Rodriquez D,  
Goeppinger SR, Surma B, Marks J,  
Rubin DT. Patient perceptions of 
fecal microbiota transplantation for 
ulcerative colitis. Inflammatory bowel 
diseases. 2013 Jun 1;19(7):1506-1513.
[3] Borody TJ, Paramsothy S,  
Agrawal G. Fecal microbiota 
transplantation: indications, methods, 
evidence, and future directions. Current 
gastroenterology reports. 2013 Aug 
1;15(8):337.
[4] Sachs RE, Edelstein CA. Ensuring 
the safe and effective FDA regulation 
of fecal microbiota transplantation. 
Journal of Law and the Biosciences. 2015 
Jul 13;2(2):396-415.
[5] Soo WT, Bryant RV, Costello SP. 
Faecal microbiota transplantation: 
indications, evidence and safety. 
Australian Prescriber. 2020 
Apr;43(2):36.
[6] Wilcox MH, McGovern BH, 
Hecht GA. The Efficacy and Safety 
of Fecal Microbiota Transplant for 
Recurrent Clostridium difficile 
infection: Current Understanding and 
Gap Analysis. InOpen Forum Infectious 
Diseases 2020 May (Vol. 7, No. 5, p. 
ofaa114). US: Oxford University Press.
[7] Lee CH, Steiner T, Petrof EO, et 
al. Frozen vs fresh fecal microbiota 
transplantation and clinical resolution 
of diarrhea in patients with recurrent 
Clostridium difficile infection: a 
randomized clinical trial. JAMA 2016; 
315:142-149.
[8] Kelly CR, Fischer M, Grinspan A,  
et al. Patients eligible for trials of 
microbebased therapeutics do not 
represent the population with recurrent 
Clostridioides difficile infection. Clin 
Gastroenterol Hepatol. In press.
[9] Dubberke ER, Lee CH,  
Orenstein R, Khanna S, Hecht G,  
Gerding DN. Results from a 
randomized, placebo-controlled clinical 
trial of a RBX2660—a microbiota-based 
drug for the prevention of recurrent 
Clostridium difficile infection. 
Clinical Infectious Diseases. 2018 Sep 
28;67(8):1198-1204.
[10] Glover SC, Burstiner S, Jones D, 
Teymoorian A, Naga Y, Silver J, Pallav K. 
E. coliSepsis Following FMT in an IgA 
Deficient IBD Subject: 2099. American 
Journal of Gastroenterology. 2019 
Oct 1;114(2019 ACG Annual Meeting 
Abstracts):S1170.
[11] Cammarota G, Masucci L,  
Ianiro G, Bibbò S, Dinoi G,  
Costamagna G, Sanguinetti M, 
Gasbarrini A. Randomised clinical 
trial: faecal microbiota transplantation 
by colonoscopy vs. vancomycin for the 
treatment of recurrent Clostridium 
difficile infection. Alimentary 
pharmacology & therapeutics. 2015 
May;41(9):835-843.
[12] Krajicek E, Fischer M, 
Allegretti JR, Kelly CR. Nuts and bolts 
of fecal microbiota transplantation. 
Clinical Gastroenterology and 
Hepatology. 2019 Jan 1;17(2):345-352.
[13] Baxter M, Colville A. Adverse events 
in faecal microbiota transplant: a review 
of the literature. Journal of Hospital 
Infection. 2016 Feb 1;92(2):117-127.
[14] Borody T, Campbell J, Torres M, 
Nowak A, Leis S. Reversal of idiopathic 
thrombocytopenic purpura [ITP] with 
fecal microbiota transplantation [FMT]. 
Am J Gastroenterol 2011;106:S352
[15] Borody T, Leis S, Campbell J, 
Torres M, Nowak A. Fecal microbiota 
Fecal Microbial Transplantation - Recent Advances, New Perspectives and Applications
14
transplantation (FMT) in multiple 
sclerosis (MS). Am J Gastroenterol 
2011;106:S352.
[16] Sbahi H, Di Palma JA. Faecal 
microbiota transplantation: 
applications and limitations in treating 
gastrointestinal disorders. BMJ open 
gastroenterology. 2016 May 1;3(1).
[17] Brandt LJ, Aroniadis OC, 
Mellow M, Kanatzar A, Kelly C, Park T, 
Stollman N, Rohlke F, Surawicz C. 
Long-Term Follow-Up of Colonoscopic 
Fecal Microbiota Transplant for 
RecurrentClostridium difficileInfection. 
American Journal of Gastroenterology. 
2012 Jul 1;107(7):1079-1087.
[18] Fang H, Fu L, Li X, Wang J, 
Xiong K, Su Y, Zhang L. Long-term 
efficacy and safety of single fecal 
microbiota transplantation for recurrent 
active ulcerative colitis. medRxiv. 2020 
Jan 1.
[19] Kelly CR, Ihunnah C, 
Fischer M, Khoruts A, Surawicz C, 
Afzali A, Aroniadis O, Barto A, Borody T, 
Giovanelli A, Gordon S. Fecal microbiota 
transplant for treatment of 
Clostridium difficile infection in 
immunocompromised patients. The 
American journal of gastroenterology. 
2014 Jul;109(7):1065.
[20] Wang JW, Kuo CH, Kuo FC, 
Wang YK, Hsu WH, Yu FJ, Hu HM, 
Hsu PI, Wang JY, Wu DC. Fecal 
microbiota transplantation: review 
and update. Journal of the Formosan 
Medical Association. 2019 Mar 
1;118:S23–S31.
[21] Goyal A, Yeh A, Bush BR, Firek BA, 
Siebold LM, Rogers MB, Kufen AD, 
Morowitz MJ. Safety, clinical response, 
and microbiome findings following 
fecal microbiota transplant in children 
with inflammatory bowel disease. 
Inflammatory bowel diseases. 2018 Jan 
18;24(2):410-421.
[22] Han YW. Fusobacterium nucleatum: 
a commensal-turned pathogen. Current 
opinion in microbiology. 2015 Feb 
1;23:141-147.
[23] Allegretti JR, Mullish BH, Kelly C, 
Fischer M. The evolution of the use 
of faecal microbiota transplantation 
and emerging therapeutic 
indications. The Lancet. 2019 Aug 
3;394(10196):420-431.
[24] Tang G, Yin W, Liu W. Is frozen 
fecal microbiota transplantation as 
effective as fresh fecal microbiota 
transplantation in patients with 
recurrent or refractory Clostridium 
difficile infection: a meta-analysis?. 
Diagnostic microbiology and infectious 
disease. 2017 Aug 1;88(4):322-329.
[25] Kao D, Roach B, 
Silva M, Beck P, Rioux K, Kaplan GG, 
Chang HJ, Coward S, Goodman KJ, 
Xu H, Madsen K. Effect of oral capsule–
vs colonoscopy-delivered fecal 
microbiota transplantation on recurrent 
Clostridium difficile infection: a 
randomized clinical trial. Jama. 2017 
Nov 28;318(20):1985-1993.
[26] Cammarota G, Ianiro G, 
Tilg H, Rajilić-Stojanović M, Kump P, 
Satokari R, Sokol H, Arkkila P, Pintus C, 
Hart A, Segal J. European consensus 
conference on faecal microbiota 
transplantation in clinical practice. Gut. 
2017 Apr 1;66(4):569-580.
[27] Emanuelsson F, Claesson BE, 
Ljungström L, Tvede M, Ung KA. 
Faecal microbiota transplantation 
and bacteriotherapy for recurrent 
Clostridium difficile infection: a 
retrospective evaluation of 31 patients. 
Scandinavian journal of infectious 
diseases. 2014 Feb 1;46(2):89-97.
[28] Mattila E, Uusitalo–
Seppälä R, Wuorela M, Lehtola L, 
Nurmi H, Ristikankare M, Moilanen V, 
Salminen K, Seppälä M, Mattila PS, 
Anttila VJ. Fecal transplantation, 
15
Safety & Potential Risks with Fecal Microbiota Transplantation
DOI: http://dx.doi.org/10.5772/intechopen.95907
through colonoscopy, is effective 
therapy for recurrent Clostridium 
difficile infection. Gastroenterology. 
2012 Mar 1;142(3):490-496.
[29] Rossen NG, MacDonald JK, de 
Vries EM, D'Haens GR, de Vos WM, 
Zoetendal EG, Ponsioen CY. Fecal 
microbiota transplantation as novel 
therapy in gastroenterology: a 
systematic review. World journal of 
gastroenterology: WJG. 2015 May 
7;21(17):5359.
[30] Marcella C, Cui B, Kelly CR, 
Ianiro G, Cammarota G, Zhang F. 
Systematic review: the global incidence 
of faecal microbiota transplantation-
related adverse events from 2000 to 
2020. Alimentary Pharmacology & 
Therapeutics. 2020 Nov 7.
[31] Kahn SA, Gorawara-Bhat R, 
Rubin DT. Fecal bacteriotherapy for 
ulcerative colitis: patients are ready, are 
we?. Inflammatory bowel diseases. 2012 
Apr 1;18(4):676-684.
[32] Bunnik EM, Aarts N, Chen LA. 
Physicians must discuss potential 
long-term risks of fecal microbiota 
transplantation to ensure informed 
consent. The American Journal of 
Bioethics. 2017 May 4;17(5):61-63.
[33] Turnbaugh PJ, Ley RE, 
Mahowald MA, Magrini V, Mardis ER, 
Gordon JI. An obesity-associated gut 
microbiome with increased capacity 
for energy harvest. nature. 2006 
Dec;444(7122):1027.
[34] Bercik P, Denou E, Collins J,  
Jackson W, Lu J, Jury J, Deng Y, 
Blennerhassett P, Macri J, McCoy KD, 
Verdu EF. The intestinal microbiota 
affect central levels of brain-derived 
neurotropic factor and behavior in 
mice. Gastroenterology. 2011 Aug 
1;141(2):599-609.
[35] Long C, Yu Y, Cui B, et al. A novel 
quick transendoscopic enteral tubing in 
mid-gut: technique and training with 
video. BMC Gastroenterol. 2018;18:37.
[36] Ekekezie C, Perler BK, 
Wexler A, Duff C, Lillis CJ, Kelly CR. 
Understanding the scope of do-it-
yourself fecal microbiota transplant. 
Am J Gastroenterol. 2020;115: 
603-607.
[37] Cottone M, Pietrosi G, 
Martorana G, Casa A, Pecoraro G, 
Oliva L, Orlando A, Rosselli M, Rizzo A, 
Pagliaro L. Prevalence of cytomegalovirus 
infection in severe refractory ulcerative 
and Crohn’s colitis. The American 
journal of gastroenterology. 2001 Mar 
1;96(3):773-775.
[38] Bunnik EM, Janssens AC, 
Schermer MH. A tiered-layered-
staged model for informed consent in 
personal genome testing. European 
Journal of Human Genetics. 2013 
Jun;21(6):596-601.
[39] Schwartz JA. Innovation in pediatric 
surgery: the surgical innovation 
continuum and the ETHICAL model. 
Journal of Pediatric Surgery. 2014 Apr 
1;49(4):639-645.
[40] Broekman ML, Carrière ME, 
Bredenoord AL. Surgical innovation: 
the ethical agenda: a systematic review. 
Medicine. 2016 Jun;95(25).
[41] Ye ZN, Xia HH, Zhang R, Li L, 
Wu LH, Liu XJ, Xie WR, He XX. The 
Efficacy of Washed Microbiota 
Transplantation on Helicobacter 
pylori Eradication: A Pilot Study. 
Gastroenterology Research and Practice. 
2020 Oct 19;2020.
[42] Zhang T, Lu G, Zhao Z, Liu Y, 
Shen Q, Li P, Chen Y, Yin H, Wang H, 
Marcella C, Cui B. Washed microbiota 
transplantation vs. manual fecal 
microbiota transplantation: clinical 
findings, animal studies and in vitro 
screening. Protein & Cell. 2020 Jan 
9:1-6.
Fecal Microbial Transplantation - Recent Advances, New Perspectives and Applications
16
[43] Fecal Microbiota Transplantation-
standardization Study Group. Nanjing 
consensus on methodology of 
washed microbiota transplantation. 
Chinese medical journal. 2020 Oct 
5;133(19):2330-2332.
[44] Ianiro G, Mullish BH, Kelly CR, 
Kassam Z, Kuijper EJ, Ng SC, Iqbal TH, 
Allegretti JR, Bibbò S, Sokol H, Zhang F. 
Reorganisation of faecal microbiota 
transplant services during the 







[46] Allen J, Sears CL. Impact of the 
gut microbiome on the genome and 
epigenome of colon epithelial cells: 
contributions to colorectal cancer 
development. Genome medicine. 2019 
Dec 1;11(1):11.
[47] Dailey FE, Turse EP, Daglilar E, 
Tahan V. The dirty aspects of fecal 
microbiota transplantation: a review of 
its adverse effects and complications. 
Current opinion in pharmacology. 2019 
Dec 1;49:29-33.
[48] Abu-Sbeih H, Ali FS, Wang Y.  
Clinical review on the utility of 
fecal microbiota transplantation in 
immunocompromised patients. Current 
gastroenterology reports. 2019 Mar 
1;21(3):8.
